Himalaya Early Access Program

NCT05345678 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

AstraZeneca